Connect with us

Life Sciences

AMA and Moziware to Revolutionize Remote Collaboration for Frontline Workers by Bringing Xperteye on & Live on Cimo Next-Gen Smart Glasses

AMA and moziware to revolutionize remote collaboration for frontline workers by bringing XpertEye On & Live on cimo next-gen smart glasses…

Published

on

This article was originally published by AITHORITY
AMA and Moziware to Revolutionize Remote Collaboration for Frontline Workers by Bringing Xperteye on & Live on Cimo Next-Gen Smart Glasses

AMA and moziware to revolutionize remote collaboration for frontline workers by bringing XpertEye On & Live on cimo next-gen smart glasses

AMA a pioneer in Assisted Reality solutions, and moziware, a provider of leading-edge wearable technologies of Industrial Metaverse announced their global strategic partnership to reshape remote collaboration by combining AMA’s brand new XpertEye On & Live remote assistance solution with moziware’s next-gen cimo smart glasses.

AI and ML NewsAI: Continuing the Chase for Brain-Level Efficiency

With AMA‘s On & Live solution, it only takes just one click on cimo to start collaborating and benefit from full HD video quality with 1080p image resolution, extremely accurate white balance settings, and industrial noise cancellation. Equipped with AMA’s AR-powered remote collaboration solution and the cimo ultra-compact and lightweight smart glasses, frontline workers across manufacturing, audit, telco, healthcare, and other industries can remotely collaborate, complete complex tasks together, and resolve issues smarter, faster, and safer.

“moziware is honored to have AMA as our strategic partner. Through relentless teamwork, we have the latest XpertEye solution seamlessly integrated on cimo with exciting new features like one-button start. We believe the joint solution will revolutionize how frontline workers collaborate and operate in the industrial 4.0 era”, said Dr. Li Bo, CEO of moziware.

“AMA is proud to have teamed up with moziware since 2021 to propose today the latest in voice-activated, hands-free, remote collaboration. Our aggressively priced and easy-to-use solution will help improve safety, efficiency, and productivity of frontline workers around the world”, said Christian Guillemot, co-founder and CEO of AMA.

Recommended AI News: CloudNC Raises $45 Million to Deliver Autonomous Manufacturing

With eight years of proven experience in remote assistance solutions, AMA is helping medical institutions and industrial organizations of all sizes accelerate their digital transformation. Our market leading XpertEye Assisted Reality platform has been deployed in more than 100 countries, addressing a wide range of applications like remote diagnostics, inspection, scheduling, and workflow management. These unequaled remote interactive collaboration solutions empower our customers to improve productivity, speed up resolution time, and maximize uptime.
With offices in Europe, in the USA and in the APAC region, AMA can work in every time zone and reach its customers wherever they are.
AMA is listed on Euronext Growth Paris.

AI ML in Marketing: AI and Big Data Analysis Used to Find Brands’ Emotional Connection

[To share your insights with us, please write to sghosh@martechseries.com]

The post AMA and Moziware to Revolutionize Remote Collaboration for Frontline Workers by Bringing Xperteye on & Live on Cimo Next-Gen Smart Glasses appeared first on AiThority.


diagnostics



big data

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending